The present invention describes compounds deriving from chemical reactions between saturated or monounsaturated acyl derivatives and primary amines or primary alcohols that display specific cannabinoid-like pharmacological activity without exhibiting the central unwanted side effects typical of synthetic cannabinoids or endocannabinoids acting on central cannabinoid (CB1) receptors. These compounds, having this pharmacological activity, may be utilised to prevent or to treat pathological conditions and diseases in mammals, including human subjects, that may undergo a clinical improvement upon their administration.
USE OF ENDOCANNABINOID-LIKE COMPOUNDS FOR TREATING CNS DEGENERATIVE DISORDERS
申请人:Research & Innovation S.p.A.
公开号:EP1592418B1
公开(公告)日:2017-09-06
USE IN THERAPY OF ENDOCANNABINOID-LIKE COMPOUNDS
申请人:Research & Innovation Soc. Coop. A R.L.
公开号:EP1592418A2
公开(公告)日:2005-11-09
Endocannabinoid-like compounds and their use for treating dermatitis
申请人:Research & Innovation S.p.A.
公开号:EP1900365B1
公开(公告)日:2011-03-30
HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
申请人:TARVEDA THERAPEUTICS, INC.
公开号:US20210145971A1
公开(公告)日:2021-05-20
Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.